China Pharma Holdings, Inc.: Form 10-Q for the period ended Jun 30, 2014
Filed with the SEC on Aug 14, 2014 and accepted by EDGAR at Aug 14, 2014, 16:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2014-04-01 to 2014-06-30 | $6.1m | us-gaap:Revenues |
| Revenue | 6 months2014-01-01 to 2014-06-30 | $13.2m | us-gaap:Revenues |
| Cost of revenue | 3 months2014-04-01 to 2014-06-30 | $3.7m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2014-01-01 to 2014-06-30 | $8.2m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2014-04-01 to 2014-06-30 | $2.4m | us-gaap:GrossProfit |
| Gross profit | 6 months2014-01-01 to 2014-06-30 | $5.1m | us-gaap:GrossProfit |
| Operating income | 3 months2014-04-01 to 2014-06-30 | −$8.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2014-01-01 to 2014-06-30 | −$10.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2014-04-01 to 2014-06-30 | −$113.4k | us-gaap:InterestExpense |
| Interest expense | 6 months2014-01-01 to 2014-06-30 | −$169.8k | us-gaap:InterestExpense |
| Income tax | 3 months2014-04-01 to 2014-06-30 | $19.2k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2014-01-01 to 2014-06-30 | $38.5k | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months2014-04-01 to 2014-06-30 | −$0.20 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2014-01-01 to 2014-06-30 | −$0.25 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2014-04-01 to 2014-06-30 | −$0.20 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2014-01-01 to 2014-06-30 | −$0.25 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months2014-01-01 to 2014-06-30 | $2.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2014-06-30 | $4.4m | us-gaap:Cash |
| Current assets | At period end2014-06-30 | $69.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2014-06-30 | $146.0m | us-gaap:Assets |
| Current liabilities | At period end2014-06-30 | $11.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2014-06-30 | $25.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2014-06-30 | $120.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001010549-14-000422. Last ingested by Listed: Nov 11, 2026, 00:23 ET. Listed shows no prices and gives no investment advice.